Cargando…

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab

Detalles Bibliográficos
Autores principales:	Strüßmann, Tim, Jung, Johannes, Heinz, Jürgen, Duque Afonso, Jesus, Wäsch, Ralph, Engelhardt, Monika, Duyster, Justus, Finke, Jürgen, Marks, Reinhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807464/ https://www.ncbi.nlm.nih.gov/pubmed/36394581 http://dx.doi.org/10.1007/s00277-022-05035-y

Ejemplares similares

The impact of pulmonary function in patients undergoing autologous stem cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2021)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
por: Greil, Christine, et al.
Publicado: (2019)

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
por: Rettig, Andrés R., et al.
Publicado: (2021)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2021)

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2020)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2020)

Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2021)

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
por: Vianelli, Nicola, et al.
Publicado: (2022)

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
por: Zufferey, Anne, et al.
Publicado: (2017)

The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
por: Hughes, David
Publicado: (2022)

Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
por: Biavasco, Francesca, et al.
Publicado: (2022)

Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation
por: Waterhouse, Miguel, et al.
Publicado: (2022)

Immune Thrombocytopenia (ITP) Secondary to Subclinical Hashimoto’s Thyroiditis: Role of Levothyroxine in Improving the Clinical Outcome of ITP
por: Tahir, Hassan, et al.
Publicado: (2016)

Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP
por: Jawed, Muzamil, et al.
Publicado: (2021)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
por: Terrell, Deirdra R., et al.
Publicado: (2020)

Response to rituximab in children and adults with immune thrombocytopenia (ITP)
por: Harris, Emily M., et al.
Publicado: (2021)

Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
por: Gangat, Naseema, et al.
Publicado: (2022)

Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life
por: Cooper, Nichola, et al.
Publicado: (2020)

A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
por: Schäfer, Henning, et al.
Publicado: (2021)

Secondary immune thrombocytopenia (ITP) as an initial presentation of Whipple’s disease
por: Priest, David H., et al.
Publicado: (2017)

Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP)
por: González-López, Tomás José, et al.
Publicado: (2022)

Suppression of APC/C(Cdh1) has subtype specific biological effects in acute myeloid leukemia
por: Ewerth, Daniel, et al.
Publicado: (2016)

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group
por: Mingot-Castellano, M. Eva, et al.
Publicado: (2019)

Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
por: Doobaree, Indraraj Umesh, et al.
Publicado: (2019)

The Role of Leptin in Childhood Immune Thrombocytopenia (ITP): An Anti-Inflammatory Agent?
por: Thomas, Iason, et al.
Publicado: (2021)

Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives
por: Zitek, Tony, et al.
Publicado: (2022)

Reticulated Platelet Count as a Diagnostic Tool in Immune Thrombocytopenia (ITP)
por: Butt, Aqsa Javed, et al.
Publicado: (2023)

Refractory chronic “ITP”: When platelet size matters
por: Baliakas, Panagiotis, et al.
Publicado: (2018)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
por: Schnerch, Dominik, et al.
Publicado: (2017)

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
por: Mingot-Castellano, María Eva, et al.
Publicado: (2023)

Refractory severe idiopathic thrombocytopenia and treatment challenges
por: Shahnazi, Anahita, et al.
Publicado: (2023)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_80hbgrjngdn9222dsfh3g0rula